SEC Comment Letter for Black Diamond Therapeutics, Inc. (BDTX) (CIK 0001701541) (BDTX) — Nov 17, 2022

Black Diamond Therapeutics, Inc. (BDTX) (CIK 0001701541)
Date: Nov. 17, 2022 · CIK: 0001701541 · Accession: 0000000000-22-012479

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-268341

Date

November 17, 2022

Author

David M. Epstein, Ph.D.

Form

UPLOAD

Company

Black Diamond Therapeutics, Inc. (BDTX) (CIK 0001701541)

Letter

United States securities and exchange commission logo November 17, 2022 David M. Epstein, Ph.D. Chief Executive Officer Black Diamond Therapeutics, Inc. One Main Street, 14th Floor Cambridge, MA 02142 Re:Black Diamond Therapeutics, Inc. Registration Statement on Form S-3 Filed November 14, 2022 File No. 333-268341 Dear David M. Epstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert E. Puopolo, Esq.

Show Raw Text

United States securities and exchange commission logo
November 17, 2022
David M. Epstein, Ph.D.
Chief Executive Officer
Black Diamond Therapeutics, Inc.
One Main Street, 14th Floor
Cambridge, MA 02142
Re:Black Diamond Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 14, 2022
File No. 333-268341
Dear David M. Epstein:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Robert E. Puopolo, Esq.

SecProbe.io